Skip to content

Gyre Therapeutics, Inc. GYRE Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$9.86M-364%$5.94M+108%$1.58M-65.3%$3.73M-62.4%
$672K+25.6%$656K+42.3%$649K+45.8%$641K+181%$535K+28.9%
$2.58M+409%$4.6M+711%$1.15M+384%$906K+5,563%$507K+4,509%
$3.18M+2,565%$4.68M$2.09M+138%-$129K-104%
$178K+45.9%$144K$668K-3.6%$256K-82.4%$122K-47.2%
-$3.06M-255%-$1.25M+47.8%-$3.04M+63.2%$1.97M+127%
$21K-98.4%$318K-67.0%$365K+12.7%$22.35M+14,228%$1.34M+104%
$431K-86.7%$3.91M+1,793%$21.45M+257%$3.23M+187%
$3M+1,296%-$5.77M-114%$4.01M$1.83M+126%-$251K-109%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Gyre Therapeutics, Inc. generate?
Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.
What is Gyre Therapeutics, Inc.'s free cash flow?
After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.
Where does Gyre Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.